News | Oncology Diagnostics | October 25, 2017

Researchers Discover New Blood Test That May Diagnose Breast Cancer

Christiana Care and GenPro file for provisional patent on novel screening tool

Researchers Discover New Blood Test That May Diagnose Breast Cancer

October 25, 2017 — In a potential major breakthrough in breast cancer research, scientists at the Center for Translational Cancer Research (CTCR) at the Helen F. Graham Cancer Center & Research Institute of Christiana Care Health System have developed a new blood test to diagnose breast cancer.

Senior scientist Jennifer Sims-Mourtada, Ph.D., director of translational breast cancer research at the CTCR located in Newark, Del, developed the test at the CTCR with scientists from Genome Profiling LLC (GenPro).

“This simple blood test, used in combination with mammography, can be a transformative tool in the fight against breast cancer by determining whether cancer is present in the breast and whether the cancer is likely to spread,” Sims-Mourtada said. “Using this test could minimize over-diagnosis and treatment while potentially providing significant savings in healthcare-related costs. Studies have shown that mammograms alone are not optimal for diagnosing all types of breast cancer.”

The test focuses on identifying an epigenetic biomarker within circulating blood cells’ DNA that are part of the body’s immune system and is different from other diagnostic tests that target cancer tumors.

“This test is designed to monitor epigenetic DNA changes in the blood cells that could signal an early stage aggressive tumor,” Sims-Mourtada said. “We know that immune cells in the blood react differently if they are responding to an infection versus a cancer, an invasive tumor or when there is no cancer present at all.”

“Commercializing an epigenetic-based diagnostic test into a simple and cost-effective blood screening test can have huge implications for early intervention strategies in breast cancer,” said GenPro co-founder Adam Marsh, Ph.D. GenPro is a molecular information company specializing in the discovery of novel epigenetic biomarkers using its genome-wide profiling platform.

“Right now there is no truly effective method for routine monitoring of patients to follow in response to treatment for breast cancer and for possible recurrence of cancer,” Sims-Mourtada said. “Using the assay we have developed, in conjunction with routine monitoring, enables us to follow changes in the immune response to detect an increase in tumor cells over time. This test can allow for much earlier detection of recurrence or metastatic disease before it is visible with standard imaging and enable much earlier treatment.”

Christiana Care and GenPro have filed a provisional patent application with the U.S. Patent and Trademark Office as the first step in the process toward clinical trials and U.S. Food and Drug Administration (FDA) approval for this new blood screening test.

For more information: www.christianacare.org

Related Content

News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
New Studies Highlight MRI Use for Prostate Cancer Screening and Management
News | Magnetic Resonance Imaging (MRI) | May 21, 2018
Three new studies presented at the 113th annual meeting of the American Urological Association (AUA) highlight the...
ACR Urges Stricter Adherence to Lung Cancer Screening Guidelines
News | Lung Cancer | May 21, 2018
A new statement from the American College of Radiology (ACR) asserts that provider non-compliance to lung cancer...
Matrix Analytics Announces Company Rebrand to Eon
News | Artificial Intelligence | May 16, 2018
Denver-based Matrix Analytics announced the company's rebrand to Eon. The rebrand marks the expansion of Eon's...
Breast Cancer Places Greater Financial Burden on Black Women
News | Women's Health | May 16, 2018
Having breast cancer placed a significantly greater financial strain on black women than white women, according to a...
FDA's MQSA Accreditation Bodies Approved for Tomosynthesis Accreditation

Image courtesy of Fujifilm.

Feature | Mammography | May 14, 2018
On April 9, 2018, the U.S. Food and Drug Administration (FDA) announced that all four of its Mammography Quality...
Body Vision Medical Receives FDA Clearance for LungVision Tool
Technology | Lung Cancer | May 09, 2018
Body Vision Medical received clearance from the U.S. Food and Drug Administration (FDA) to market their LungVision Tool...
USPSTF Updates Recommendations for Prostate Cancer Screening
News | Prostate Cancer | May 09, 2018
The U.S. Preventive Services Task Force (USPSTF) posted a final recommendation statement and evidence summaries on...
Overlay Init